Tizanidine Liquid Preparation with EDTA for Chemical Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tizanidine formulations, primarily in tablet and capsule forms, face challenges with dysphagia compliance, inaccurate dose titration, high adverse effects, and prolonged drug action due to food intake, necessitating a stable and fast-acting liquid preparation with equivalent bioavailability.
Innovation Solution
A tizanidine liquid preparation incorporating a chelating agent like EDTA, pH adjusters, and other excipients to maintain stability and bioequivalence, with a pH range of 3.5 to 6.5, ensuring low impurities and reduced adverse effects, and rapid action regardless of food intake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If tizanidine is formulated as solid oral dosage forms (tablets/capsules), then manufacturing and storage are simplified, but compliance is poor for patients with dysphagia and dose titration is inaccurate
Solution Approach 1:
The patent changes the physical state parameter of tizanidine from solid (tablets/capsules) to liquid form. This parameter change enables accurate dose titration by allowing flexible measurement of liquid volumes, improves compliance for dysphagic patients who cannot swallow solids, and maintains manufacturing simplicity through established liquid formulation techniques.
2Ease of operation
If tizanidine liquid preparation is developed to improve compliance and dose titration, then patient compliance and dosing accuracy improve, but chemical stability deteriorates due to liquid formulation susceptibility
Solution Approach 1:
The patent introduces edetate disodium as a chelating agent intermediary that binds metal ions which would otherwise catalyze degradation of tizanidine in liquid form. This intermediary substance protects the active ingredient from chemical degradation, enabling long-term stability of the liquid preparation while maintaining the compliance and dosing accuracy benefits.
Solution Approach 2:
The patent adjusts the pH parameter of the liquid preparation to a specific range (3.5-6.5) where tizanidine exhibits both adequate solubility and enhanced chemical stability. This parameter optimization reduces degradation rates while maintaining the liquid form's advantages for compliance and dose titration.
3Duration of action of moving object
If tizanidine is administered in post-prandial conditions with solid formulations, then absorption is prolonged, but drug action speed decreases
Solution Approach 1:
The patent changes the formulation physical state from solid to liquid, which fundamentally alters the dissolution and absorption parameters. The liquid formulation eliminates the dissolution step required for solids, enabling rapid absorption even in post-prandial conditions while maintaining extended duration of action through controlled release mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liquid preparation achieves stable drug action, reduced adverse effects, and equivalent bioavailability to solid forms, with faster onset under post-prandial conditions, addressing compliance issues for vulnerable patient groups.
Implementation Method 1
liquid preparations are more susceptible to chemical instability... incorporating a chelating agent like EDTA
Implementation Method 2
pH adjusters, and other excipients to maintain stability and bioequivalence, with a pH range of 3.5 to 6.5
Data Source
AI summary
A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, a stabilizing agent and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.